aluates Reports

$ 0.0

Automative

Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Research Report 2025

Published Date: 2025-02-12

Report Code: QYRE-Auto-35Z18791

BUY CHAPTERS

Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Research Report 2025

Code: QYRE-Auto-35Z18791

Report

2025-02-12

Pages:140

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Cell and Gene Therapy (CGT) Pharmaceuticals Market Size

The global market for Cell and Gene Therapy (CGT) Pharmaceuticals was valued at US$ 16710 million in the year 2024 and is projected to reach a revised size of US$ 52080 million by 2031, growing at a CAGR of 18.9% during the forecast period.

Cell and Gene Therapy (CGT) Pharmaceuticals Market

Cell and Gene Therapy (CGT) drugs are a class of innovative treatments that treat diseases by changing the patient's cells or genes. Specifically, CGT drugs usually include: 1. Gene therapy: by introducing, deleting or repairing genes into the patient's cells, the purpose is to correct diseases caused by genetic defects or mutations. For example, gene therapy can deliver normal genes to patients through viral vectors to replace missing or defective genes.

2. Cell therapy: by changing or enhancing the patient's own cells and then re-injecting them into the body for treatment. Common cell therapies include using immune cells (such as CAR-T cells) to treat cancer or using stem cells to repair damaged tissues.

North American market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Cell and Gene Therapy (CGT) Pharmaceuticals in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Cell and Gene Therapy (CGT) Pharmaceuticals include Vericel, Castle Creek, Terumo, Nipro, BioCardia, Sanpower Group, Novartis, Gilead Sciences, Inc./Fosun Kite, BMS, JW (Cayman) Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cell and Gene Therapy (CGT) Pharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Gene Therapy (CGT) Pharmaceuticals.

The Cell and Gene Therapy (CGT) Pharmaceuticals market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cell and Gene Therapy (CGT) Pharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cell and Gene Therapy (CGT) Pharmaceuticals companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cell and Gene Therapy (CGT) Pharmaceuticals Market Report

Report Metric	Details
Report Name	Cell and Gene Therapy (CGT) Pharmaceuticals Market
Accounted market size in year	US$ 16710 million
Forecasted market size in 2031	US$ 52080 million
CAGR	18.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cell Therapy Drugs Gene Therapy Drugs
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Vericel, Castle Creek, Terumo, Nipro, BioCardia, Sanpower Group, Novartis, Gilead Sciences, Inc./Fosun Kite, BMS, JW (Cayman) Therapeutics, Legend Biotech Corp./Johnson & Johnson, Innovent Biologics, Inc./IASO Biotherapeutics, Juventas/CASI, CARsgen Therapeutics Holdings, Huadong Medicine, inno.N, lovance, Mesoblast, Takeda, Pierre fabre, Aurion Biotech, Gamida Cell, CellTrans, SiBiono Gene Technology, Ferring, Kyowa Kirin, uniQure, Roche, PTC Therapeutics, BioMarin, CSL, Sarepta, AnGes, bluebird bio, Krystal Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cell and Gene Therapy (CGT) Pharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Cell and Gene Therapy (CGT) Pharmaceuticals Market growing?

Ans: The Cell and Gene Therapy (CGT) Pharmaceuticals Market witnessing a CAGR of 18.9% during the forecast period 2025-2031.

What is the Cell and Gene Therapy (CGT) Pharmaceuticals Market size in 2031?

Ans: The Cell and Gene Therapy (CGT) Pharmaceuticals Market size in 2031 will be US$ 52080 million.

Who are the main players in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report?

Ans: The main players in the Cell and Gene Therapy (CGT) Pharmaceuticals Market are Vericel, Castle Creek, Terumo, Nipro, BioCardia, Sanpower Group, Novartis, Gilead Sciences, Inc./Fosun Kite, BMS, JW (Cayman) Therapeutics, Legend Biotech Corp./Johnson & Johnson, Innovent Biologics, Inc./IASO Biotherapeutics, Juventas/CASI, CARsgen Therapeutics Holdings, Huadong Medicine, inno.N, lovance, Mesoblast, Takeda, Pierre fabre, Aurion Biotech, Gamida Cell, CellTrans, SiBiono Gene Technology, Ferring, Kyowa Kirin, uniQure, Roche, PTC Therapeutics, BioMarin, CSL, Sarepta, AnGes, bluebird bio, Krystal Biotech

What are the Application segmentation covered in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report?

Ans: The Applications covered in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report?

Ans: The Types covered in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report are Cell Therapy Drugs, Gene Therapy Drugs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Cell Therapy Drugs

1.2.3 Gene Therapy Drugs

1.3 Market by Application

1.3.1 Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Perspective (2020-2031)

2.2 Global Cell and Gene Therapy (CGT) Pharmaceuticals Growth Trends by Region

2.2.1 Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Cell and Gene Therapy (CGT) Pharmaceuticals Historic Market Size by Region (2020-2025)

2.2.3 Cell and Gene Therapy (CGT) Pharmaceuticals Forecasted Market Size by Region (2026-2031)

2.3 Cell and Gene Therapy (CGT) Pharmaceuticals Market Dynamics

2.3.1 Cell and Gene Therapy (CGT) Pharmaceuticals Industry Trends

2.3.2 Cell and Gene Therapy (CGT) Pharmaceuticals Market Drivers

2.3.3 Cell and Gene Therapy (CGT) Pharmaceuticals Market Challenges

2.3.4 Cell and Gene Therapy (CGT) Pharmaceuticals Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cell and Gene Therapy (CGT) Pharmaceuticals Players by Revenue

3.1.1 Global Top Cell and Gene Therapy (CGT) Pharmaceuticals Players by Revenue (2020-2025)

3.1.2 Global Cell and Gene Therapy (CGT) Pharmaceuticals Revenue Market Share by Players (2020-2025)

3.2 Global Top Cell and Gene Therapy (CGT) Pharmaceuticals Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Cell and Gene Therapy (CGT) Pharmaceuticals Revenue

3.4 Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Concentration Ratio

3.4.1 Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cell and Gene Therapy (CGT) Pharmaceuticals Revenue in 2024

3.5 Global Key Players of Cell and Gene Therapy (CGT) Pharmaceuticals Head office and Area Served

3.6 Global Key Players of Cell and Gene Therapy (CGT) Pharmaceuticals, Product and Application

3.7 Global Key Players of Cell and Gene Therapy (CGT) Pharmaceuticals, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Cell and Gene Therapy (CGT) Pharmaceuticals Breakdown Data by Type

4.1 Global Cell and Gene Therapy (CGT) Pharmaceuticals Historic Market Size by Type (2020-2025)

4.2 Global Cell and Gene Therapy (CGT) Pharmaceuticals Forecasted Market Size by Type (2026-2031)

5 Cell and Gene Therapy (CGT) Pharmaceuticals Breakdown Data by Application

5.1 Global Cell and Gene Therapy (CGT) Pharmaceuticals Historic Market Size by Application (2020-2025)

5.2 Global Cell and Gene Therapy (CGT) Pharmaceuticals Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size (2020-2031)

6.2 North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025)

6.4 North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Size (2020-2031)

7.2 Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025)

7.4 Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Size (2020-2031)

8.2 Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Region (2020-2025)

8.4 Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size (2020-2031)

9.2 Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025)

9.4 Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Size (2020-2031)

10.2 Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025)

10.4 Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Vericel

11.1.1 Vericel Company Details

11.1.2 Vericel Business Overview

11.1.3 Vericel Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.1.4 Vericel Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.1.5 Vericel Recent Development

11.2 Castle Creek

11.2.1 Castle Creek Company Details

11.2.2 Castle Creek Business Overview

11.2.3 Castle Creek Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.2.4 Castle Creek Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.2.5 Castle Creek Recent Development

11.3 Terumo

11.3.1 Terumo Company Details

11.3.2 Terumo Business Overview

11.3.3 Terumo Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.3.4 Terumo Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.3.5 Terumo Recent Development

11.4 Nipro

11.4.1 Nipro Company Details

11.4.2 Nipro Business Overview

11.4.3 Nipro Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.4.4 Nipro Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.4.5 Nipro Recent Development

11.5 BioCardia

11.5.1 BioCardia Company Details

11.5.2 BioCardia Business Overview

11.5.3 BioCardia Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.5.4 BioCardia Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.5.5 BioCardia Recent Development

11.6 Sanpower Group

11.6.1 Sanpower Group Company Details

11.6.2 Sanpower Group Business Overview

11.6.3 Sanpower Group Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.6.4 Sanpower Group Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.6.5 Sanpower Group Recent Development

11.7 Novartis

11.7.1 Novartis Company Details

11.7.2 Novartis Business Overview

11.7.3 Novartis Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.7.4 Novartis Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.7.5 Novartis Recent Development

11.8 Gilead Sciences, Inc./Fosun Kite

11.8.1 Gilead Sciences, Inc./Fosun Kite Company Details

11.8.2 Gilead Sciences, Inc./Fosun Kite Business Overview

11.8.3 Gilead Sciences, Inc./Fosun Kite Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.8.4 Gilead Sciences, Inc./Fosun Kite Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.8.5 Gilead Sciences, Inc./Fosun Kite Recent Development

11.9 BMS

11.9.1 BMS Company Details

11.9.2 BMS Business Overview

11.9.3 BMS Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.9.4 BMS Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.9.5 BMS Recent Development

11.10 JW (Cayman) Therapeutics

11.10.1 JW (Cayman) Therapeutics Company Details

11.10.2 JW (Cayman) Therapeutics Business Overview

11.10.3 JW (Cayman) Therapeutics Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.10.4 JW (Cayman) Therapeutics Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.10.5 JW (Cayman) Therapeutics Recent Development

11.11 Legend Biotech Corp./Johnson & Johnson

11.11.1 Legend Biotech Corp./Johnson & Johnson Company Details

11.11.2 Legend Biotech Corp./Johnson & Johnson Business Overview

11.11.3 Legend Biotech Corp./Johnson & Johnson Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.11.4 Legend Biotech Corp./Johnson & Johnson Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.11.5 Legend Biotech Corp./Johnson & Johnson Recent Development

11.12 Innovent Biologics, Inc./IASO Biotherapeutics

11.12.1 Innovent Biologics, Inc./IASO Biotherapeutics Company Details

11.12.2 Innovent Biologics, Inc./IASO Biotherapeutics Business Overview

11.12.3 Innovent Biologics, Inc./IASO Biotherapeutics Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.12.4 Innovent Biologics, Inc./IASO Biotherapeutics Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.12.5 Innovent Biologics, Inc./IASO Biotherapeutics Recent Development

11.13 Juventas/CASI

11.13.1 Juventas/CASI Company Details

11.13.2 Juventas/CASI Business Overview

11.13.3 Juventas/CASI Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.13.4 Juventas/CASI Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.13.5 Juventas/CASI Recent Development

11.14 CARsgen Therapeutics Holdings

11.14.1 CARsgen Therapeutics Holdings Company Details

11.14.2 CARsgen Therapeutics Holdings Business Overview

11.14.3 CARsgen Therapeutics Holdings Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.14.4 CARsgen Therapeutics Holdings Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.14.5 CARsgen Therapeutics Holdings Recent Development

11.15 Huadong Medicine

11.15.1 Huadong Medicine Company Details

11.15.2 Huadong Medicine Business Overview

11.15.3 Huadong Medicine Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.15.4 Huadong Medicine Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.15.5 Huadong Medicine Recent Development

11.16 inno.N

11.16.1 inno.N Company Details

11.16.2 inno.N Business Overview

11.16.3 inno.N Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.16.4 inno.N Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.16.5 inno.N Recent Development

11.17 lovance

11.17.1 lovance Company Details

11.17.2 lovance Business Overview

11.17.3 lovance Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.17.4 lovance Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.17.5 lovance Recent Development

11.18 Mesoblast

11.18.1 Mesoblast Company Details

11.18.2 Mesoblast Business Overview

11.18.3 Mesoblast Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.18.4 Mesoblast Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.18.5 Mesoblast Recent Development

11.19 Takeda

11.19.1 Takeda Company Details

11.19.2 Takeda Business Overview

11.19.3 Takeda Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.19.4 Takeda Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.19.5 Takeda Recent Development

11.20 Pierre fabre

11.20.1 Pierre fabre Company Details

11.20.2 Pierre fabre Business Overview

11.20.3 Pierre fabre Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.20.4 Pierre fabre Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.20.5 Pierre fabre Recent Development

11.21 Aurion Biotech

11.21.1 Aurion Biotech Company Details

11.21.2 Aurion Biotech Business Overview

11.21.3 Aurion Biotech Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.21.4 Aurion Biotech Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.21.5 Aurion Biotech Recent Development

11.22 Gamida Cell

11.22.1 Gamida Cell Company Details

11.22.2 Gamida Cell Business Overview

11.22.3 Gamida Cell Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.22.4 Gamida Cell Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.22.5 Gamida Cell Recent Development

11.23 CellTrans

11.23.1 CellTrans Company Details

11.23.2 CellTrans Business Overview

11.23.3 CellTrans Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.23.4 CellTrans Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.23.5 CellTrans Recent Development

11.24 SiBiono Gene Technology

11.24.1 SiBiono Gene Technology Company Details

11.24.2 SiBiono Gene Technology Business Overview

11.24.3 SiBiono Gene Technology Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.24.4 SiBiono Gene Technology Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.24.5 SiBiono Gene Technology Recent Development

11.25 Ferring

11.25.1 Ferring Company Details

11.25.2 Ferring Business Overview

11.25.3 Ferring Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.25.4 Ferring Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.25.5 Ferring Recent Development

11.26 Kyowa Kirin

11.26.1 Kyowa Kirin Company Details

11.26.2 Kyowa Kirin Business Overview

11.26.3 Kyowa Kirin Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.26.4 Kyowa Kirin Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.26.5 Kyowa Kirin Recent Development

11.27 uniQure

11.27.1 uniQure Company Details

11.27.2 uniQure Business Overview

11.27.3 uniQure Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.27.4 uniQure Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.27.5 uniQure Recent Development

11.28 Roche

11.28.1 Roche Company Details

11.28.2 Roche Business Overview

11.28.3 Roche Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.28.4 Roche Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.28.5 Roche Recent Development

11.29 PTC Therapeutics

11.29.1 PTC Therapeutics Company Details

11.29.2 PTC Therapeutics Business Overview

11.29.3 PTC Therapeutics Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.29.4 PTC Therapeutics Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.29.5 PTC Therapeutics Recent Development

11.30 BioMarin

11.30.1 BioMarin Company Details

11.30.2 BioMarin Business Overview

11.30.3 BioMarin Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.30.4 BioMarin Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.30.5 BioMarin Recent Development

11.31 CSL

11.31.1 CSL Company Details

11.31.2 CSL Business Overview

11.31.3 CSL Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.31.4 CSL Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.31.5 CSL Recent Development

11.32 Sarepta

11.32.1 Sarepta Company Details

11.32.2 Sarepta Business Overview

11.32.3 Sarepta Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.32.4 Sarepta Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.32.5 Sarepta Recent Development

11.33 AnGes

11.33.1 AnGes Company Details

11.33.2 AnGes Business Overview

11.33.3 AnGes Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.33.4 AnGes Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.33.5 AnGes Recent Development

11.34 bluebird bio

11.34.1 bluebird bio Company Details

11.34.2 bluebird bio Business Overview

11.34.3 bluebird bio Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.34.4 bluebird bio Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.34.5 bluebird bio Recent Development

11.35 Krystal Biotech

11.35.1 Krystal Biotech Company Details

11.35.2 Krystal Biotech Business Overview

11.35.3 Krystal Biotech Cell and Gene Therapy (CGT) Pharmaceuticals Introduction

11.35.4 Krystal Biotech Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

11.35.5 Krystal Biotech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Cell Therapy Drugs

Table 3. Key Players of Gene Therapy Drugs

Table 4. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Region (2020-2025)

Table 8. Global Cell and Gene Therapy (CGT) Pharmaceuticals Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Region (2026-2031)

Table 10. Cell and Gene Therapy (CGT) Pharmaceuticals Market Trends

Table 11. Cell and Gene Therapy (CGT) Pharmaceuticals Market Drivers

Table 12. Cell and Gene Therapy (CGT) Pharmaceuticals Market Challenges

Table 13. Cell and Gene Therapy (CGT) Pharmaceuticals Market Restraints

Table 14. Global Cell and Gene Therapy (CGT) Pharmaceuticals Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Players (2020-2025)

Table 16. Global Top Cell and Gene Therapy (CGT) Pharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals as of 2024)

Table 17. Ranking of Global Top Cell and Gene Therapy (CGT) Pharmaceuticals Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Cell and Gene Therapy (CGT) Pharmaceuticals Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Cell and Gene Therapy (CGT) Pharmaceuticals, Headquarters and Area Served

Table 20. Global Key Players of Cell and Gene Therapy (CGT) Pharmaceuticals, Product and Application

Table 21. Global Key Players of Cell and Gene Therapy (CGT) Pharmaceuticals, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Cell and Gene Therapy (CGT) Pharmaceuticals Revenue Market Share by Type (2020-2025)

Table 25. Global Cell and Gene Therapy (CGT) Pharmaceuticals Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Cell and Gene Therapy (CGT) Pharmaceuticals Revenue Market Share by Type (2026-2031)

Table 27. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Cell and Gene Therapy (CGT) Pharmaceuticals Revenue Market Share by Application (2020-2025)

Table 29. Global Cell and Gene Therapy (CGT) Pharmaceuticals Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Cell and Gene Therapy (CGT) Pharmaceuticals Revenue Market Share by Application (2026-2031)

Table 31. North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Country (2026-2031) & (US$ Million)

Table 46. Vericel Company Details

Table 47. Vericel Business Overview

Table 48. Vericel Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 49. Vericel Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 50. Vericel Recent Development

Table 51. Castle Creek Company Details

Table 52. Castle Creek Business Overview

Table 53. Castle Creek Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 54. Castle Creek Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 55. Castle Creek Recent Development

Table 56. Terumo Company Details

Table 57. Terumo Business Overview

Table 58. Terumo Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 59. Terumo Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 60. Terumo Recent Development

Table 61. Nipro Company Details

Table 62. Nipro Business Overview

Table 63. Nipro Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 64. Nipro Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 65. Nipro Recent Development

Table 66. BioCardia Company Details

Table 67. BioCardia Business Overview

Table 68. BioCardia Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 69. BioCardia Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 70. BioCardia Recent Development

Table 71. Sanpower Group Company Details

Table 72. Sanpower Group Business Overview

Table 73. Sanpower Group Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 74. Sanpower Group Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 75. Sanpower Group Recent Development

Table 76. Novartis Company Details

Table 77. Novartis Business Overview

Table 78. Novartis Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 79. Novartis Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 80. Novartis Recent Development

Table 81. Gilead Sciences, Inc./Fosun Kite Company Details

Table 82. Gilead Sciences, Inc./Fosun Kite Business Overview

Table 83. Gilead Sciences, Inc./Fosun Kite Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 84. Gilead Sciences, Inc./Fosun Kite Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 85. Gilead Sciences, Inc./Fosun Kite Recent Development

Table 86. BMS Company Details

Table 87. BMS Business Overview

Table 88. BMS Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 89. BMS Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 90. BMS Recent Development

Table 91. JW (Cayman) Therapeutics Company Details

Table 92. JW (Cayman) Therapeutics Business Overview

Table 93. JW (Cayman) Therapeutics Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 94. JW (Cayman) Therapeutics Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 95. JW (Cayman) Therapeutics Recent Development

Table 96. Legend Biotech Corp./Johnson & Johnson Company Details

Table 97. Legend Biotech Corp./Johnson & Johnson Business Overview

Table 98. Legend Biotech Corp./Johnson & Johnson Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 99. Legend Biotech Corp./Johnson & Johnson Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 100. Legend Biotech Corp./Johnson & Johnson Recent Development

Table 101. Innovent Biologics, Inc./IASO Biotherapeutics Company Details

Table 102. Innovent Biologics, Inc./IASO Biotherapeutics Business Overview

Table 103. Innovent Biologics, Inc./IASO Biotherapeutics Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 104. Innovent Biologics, Inc./IASO Biotherapeutics Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 105. Innovent Biologics, Inc./IASO Biotherapeutics Recent Development

Table 106. Juventas/CASI Company Details

Table 107. Juventas/CASI Business Overview

Table 108. Juventas/CASI Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 109. Juventas/CASI Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 110. Juventas/CASI Recent Development

Table 111. CARsgen Therapeutics Holdings Company Details

Table 112. CARsgen Therapeutics Holdings Business Overview

Table 113. CARsgen Therapeutics Holdings Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 114. CARsgen Therapeutics Holdings Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 115. CARsgen Therapeutics Holdings Recent Development

Table 116. Huadong Medicine Company Details

Table 117. Huadong Medicine Business Overview

Table 118. Huadong Medicine Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 119. Huadong Medicine Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 120. Huadong Medicine Recent Development

Table 121. inno.N Company Details

Table 122. inno.N Business Overview

Table 123. inno.N Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 124. inno.N Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 125. inno.N Recent Development

Table 126. lovance Company Details

Table 127. lovance Business Overview

Table 128. lovance Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 129. lovance Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 130. lovance Recent Development

Table 131. Mesoblast Company Details

Table 132. Mesoblast Business Overview

Table 133. Mesoblast Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 134. Mesoblast Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 135. Mesoblast Recent Development

Table 136. Takeda Company Details

Table 137. Takeda Business Overview

Table 138. Takeda Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 139. Takeda Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 140. Takeda Recent Development

Table 141. Pierre fabre Company Details

Table 142. Pierre fabre Business Overview

Table 143. Pierre fabre Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 144. Pierre fabre Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 145. Pierre fabre Recent Development

Table 146. Aurion Biotech Company Details

Table 147. Aurion Biotech Business Overview

Table 148. Aurion Biotech Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 149. Aurion Biotech Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 150. Aurion Biotech Recent Development

Table 151. Gamida Cell Company Details

Table 152. Gamida Cell Business Overview

Table 153. Gamida Cell Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 154. Gamida Cell Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 155. Gamida Cell Recent Development

Table 156. CellTrans Company Details

Table 157. CellTrans Business Overview

Table 158. CellTrans Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 159. CellTrans Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 160. CellTrans Recent Development

Table 161. SiBiono Gene Technology Company Details

Table 162. SiBiono Gene Technology Business Overview

Table 163. SiBiono Gene Technology Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 164. SiBiono Gene Technology Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 165. SiBiono Gene Technology Recent Development

Table 166. Ferring Company Details

Table 167. Ferring Business Overview

Table 168. Ferring Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 169. Ferring Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 170. Ferring Recent Development

Table 171. Kyowa Kirin Company Details

Table 172. Kyowa Kirin Business Overview

Table 173. Kyowa Kirin Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 174. Kyowa Kirin Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 175. Kyowa Kirin Recent Development

Table 176. uniQure Company Details

Table 177. uniQure Business Overview

Table 178. uniQure Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 179. uniQure Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 180. uniQure Recent Development

Table 181. Roche Company Details

Table 182. Roche Business Overview

Table 183. Roche Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 184. Roche Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 185. Roche Recent Development

Table 186. PTC Therapeutics Company Details

Table 187. PTC Therapeutics Business Overview

Table 188. PTC Therapeutics Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 189. PTC Therapeutics Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 190. PTC Therapeutics Recent Development

Table 191. BioMarin Company Details

Table 192. BioMarin Business Overview

Table 193. BioMarin Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 194. BioMarin Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 195. BioMarin Recent Development

Table 196. CSL Company Details

Table 197. CSL Business Overview

Table 198. CSL Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 199. CSL Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 200. CSL Recent Development

Table 201. Sarepta Company Details

Table 202. Sarepta Business Overview

Table 203. Sarepta Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 204. Sarepta Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 205. Sarepta Recent Development

Table 206. AnGes Company Details

Table 207. AnGes Business Overview

Table 208. AnGes Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 209. AnGes Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 210. AnGes Recent Development

Table 211. bluebird bio Company Details

Table 212. bluebird bio Business Overview

Table 213. bluebird bio Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 214. bluebird bio Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 215. bluebird bio Recent Development

Table 216. Krystal Biotech Company Details

Table 217. Krystal Biotech Business Overview

Table 218. Krystal Biotech Cell and Gene Therapy (CGT) Pharmaceuticals Product

Table 219. Krystal Biotech Revenue in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025) & (US$ Million)

Table 220. Krystal Biotech Recent Development

Table 221. Research Programs/Design for This Report

Table 222. Key Data Information from Secondary Sources

Table 223. Key Data Information from Primary Sources

Table 224. Authors List of This Report

List of Figures

Figure 1. Cell and Gene Therapy (CGT) Pharmaceuticals Picture

Figure 2. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Type: 2024 VS 2031

Figure 4. Cell Therapy Drugs Features

Figure 5. Gene Therapy Drugs Features

Figure 6. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Clinic Case Studies

Figure 10. Other Case Studies

Figure 11. Cell and Gene Therapy (CGT) Pharmaceuticals Report Years Considered

Figure 12. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Region: 2024 VS 2031

Figure 15. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Players in 2024

Figure 16. Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by Cell and Gene Therapy (CGT) Pharmaceuticals Revenue in 2024

Figure 18. North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Country (2020-2031)

Figure 20. United States Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Country (2020-2031)

Figure 24. Germany Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Region (2020-2031)

Figure 32. China Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Country (2020-2031)

Figure 40. Mexico Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Cell and Gene Therapy (CGT) Pharmaceuticals Market Share by Country (2020-2031)

Figure 44. Turkey Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Cell and Gene Therapy (CGT) Pharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Vericel Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 48. Castle Creek Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 49. Terumo Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 50. Nipro Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 51. BioCardia Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 52. Sanpower Group Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 53. Novartis Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 54. Gilead Sciences, Inc./Fosun Kite Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 55. BMS Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 56. JW (Cayman) Therapeutics Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 57. Legend Biotech Corp./Johnson & Johnson Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 58. Innovent Biologics, Inc./IASO Biotherapeutics Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 59. Juventas/CASI Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 60. CARsgen Therapeutics Holdings Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 61. Huadong Medicine Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 62. inno.N Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 63. lovance Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 64. Mesoblast Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 65. Takeda Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 66. Pierre fabre Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 67. Aurion Biotech Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 68. Gamida Cell Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 69. CellTrans Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 70. SiBiono Gene Technology Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 71. Ferring Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 72. Kyowa Kirin Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 73. uniQure Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 74. Roche Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 75. PTC Therapeutics Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 76. BioMarin Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 77. CSL Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 78. Sarepta Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 79. AnGes Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 80. bluebird bio Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 81. Krystal Biotech Revenue Growth Rate in Cell and Gene Therapy (CGT) Pharmaceuticals Business (2020-2025)

Figure 82. Bottom-up and Top-down Approaches for This Report

Figure 83. Data Triangulation

Figure 84. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Research Report 2025

Published Date: 2025-02-12

Report Code: QYRE-Auto-35Z18791

Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Research Report 2025

FEATURED COMPANIES

Cell and Gene Therapy (CGT) Pharmaceuticals Market Size

Cell and Gene Therapy (CGT) Pharmaceuticals Market

Scope of Cell and Gene Therapy (CGT) Pharmaceuticals Market Report

Chapter Outline

FAQ for this report

How fast is Cell and Gene Therapy (CGT) Pharmaceuticals Market growing?

What is the Cell and Gene Therapy (CGT) Pharmaceuticals Market size in 2031?

Who are the main players in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report?

What are the Application segmentation covered in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report?

What are the Type segmentation covered in the Cell and Gene Therapy (CGT) Pharmaceuticals Market report?

FEATURED COMPANIES